Supplementing with IL-2 to Verifiably eRadicate Radiological Progression (NCT07063875)

A recent clinical trial found that after 36 months, patients taking tebentafusp had a median survival of 21.6 months, compared to 16.9 months for those in the control group. Since recruitment for tebentafusp in metastatic uveal melanoma (mUM) has ended, a new trial is starting to test whether adding IL-2 can help overcome resistance to tebentafusp and improve its effectiveness. This study aims to answer: Can combining tebentafusp with IL-2 improve tumor response and overall survival? What are the benefits and side effects of this combination therapy? All participants will receive both IL-2 and tebentafusp in a 28-day treatment cycle. The dosing schedule is as follows: Cycle1 Day1-3 IL-2, Day4 Tebentafusp, Day 10 IL-2, Day 11 Tebentafusp, Day 17 IL-2, Day 18 Tebentafusp, Day 24 IL-2, Day 25 Tebentafusp. Cycle 2 & thereafter: Day 1 IL-2, Day 2 Tebentafusp, Day 8 IL-2, Day 9 Tebentafusp, Day 15 IL-2, Day 16 Tebentafusp, Day 22 IL-2, Day 23 Tebentafusp.

Trial phase

Phase 1

Trial participation type

This trial has been designed for the Clinical Research of a Drug.

Principal investigator

Dr Malaka Ameratunga

Key inclusion data

You may be eligible for this study if you have metastatic uveal malanoma or unresectable uveal melanoma with progression on Tebentafusp.